Skip to main content
. 2015 Dec 9;2015(12):CD007245. doi: 10.1002/14651858.CD007245.pub3

4. Omar 2010.

  Treatment Group Control P value
12 months follow‐up      
Randomised 75 75  
Completed 60 63  
       
Abnormal vaginal bleeding or spotting 22 2 <0.001
Breast cancer‐related deaths 0 1  
       
24 months follow‐up      
Completed 59 62  
       
Abnormal vaginal bleeding or spotting 7 2 0.08
Endometrial polyps 1 10 0.02
Endometrial hyperplasia 0 0  
Fibroids 2 4 1.0